Teva

News

Allergan, Teva considering $5bn play to shake off opioid han...

AbbVie's Allergan subsidiary and Teva are reportedly considering making a $5 billion-plus offer to try to bring opioid liability lawsuits to a conclusion.

News

Teva's long-acting schizophrenia drug rejected by FDA

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone

News

BMS' cash cow Revlimid faces first generic rivals in US

Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales

News

Teva will appeal opioid liability ruling in New York trial

The jury in a new York trial has found that Teva Pharmaceuticals played a role in fuelling the opioid crisis in the US, and should

Sales & Marketing

Sustained healthcare systems need sustainable pharma busines...

COVID-19 demonstrated the importance of robust supply chains and the dangers of an over reliance on overseas manufacturing.

News

Illustration of a nerve cell on a colored background with light effects

EU panel rejects Pfizer's tanezumab for osteoarthritis pain

Any lingering hope that Pfizer may finally get a regulatory approval for its nerve growth factor (NGF) inhibitor tanezumab looks to have been dashed after the EMA's human medicines committe

Allergan, Teva considering $5bn play to shake off opioid han...

Teva's long-acting schizophrenia drug rejected by FDA

BMS' cash cow Revlimid faces first generic rivals in US

Teva will appeal opioid liability ruling in New York trial

Sustained healthcare systems need sustainable pharma busines...

EU panel rejects Pfizer's tanezumab for osteoarthritis pain

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Teva

Editor's Picks